Skip to main content

HALO Halozyme Therapeutics, Inc.

Healthcare

128.95 -1.96 -1.50% Close 11/2
Since 2024-12-02 +169.4%
Open
131.44
High
131.89
Low
127.52
Prev close
130.91
Volume
3.4M
Amplitude
3.34%
P/E
39.1
P/B
103.5
Revenue YoY (TTM)
+41.1%
52W 61.23 134.00

Is Halozyme Therapeutics, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Quality: Strong, Growth: Good, Momentum: Strong, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E 39.08 77th percentile Pricey
Price / book 103.51 99th percentile Expensive
Free-cash-flow yield (%) 5.43 68th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Strong All 3 indicators are Top.
ROE, TTM (%) 288.13 97th percentile Top
Operating margin, TTM (%) 56.77 93th percentile Top
FCF margin, TTM (%) 48.46 92th percentile Top
Quality Factor Investing: A US Quality Value Backtest
Growth Good Revenue growth, TTM YoY is Top, but Diluted EPS growth, TTM YoY is Average.
Revenue growth, TTM YoY (%) 41.15 85th percentile Top
Diluted EPS growth, TTM YoY (%) -23.34 45th percentile Average
Momentum Strong All 2 indicators are Top.
60-day return (%) 52.65 98th percentile Top
240-day return (%) 86.93 94th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 250,000,790 94th percentile Top
60-day annualized volatility (%) 49.41 55th percentile Average
Factor Investing Explained: 10 Classic Factors in US Stocks

Halozyme Therapeutics, Inc. (HALO) today

3 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Halozyme Therapeutics, Inc. to every stock like it

AI finds several complementary traits of Halozyme Therapeutics, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. (HALO) peers and tracking

Watchlist

This page refreshes daily after the close. Add Halozyme Therapeutics, Inc. to your watchlist to track signal changes on your next visit.

Halozyme Therapeutics, Inc. (HALO) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

23 historical occurrences (since 2017-01-09)

Average forward return after 52-week adjusted-price high

20-day: Win 52.2%, Sample 23, Median +0.6%, Excess -1.66%, Beat mkt rate 43.5%

60-day: Win 47.8%, Sample 23, Median -4.34%, Excess +1.73%, Beat mkt rate 43.5%

120-day: Win 72.7%, Sample 22, Median +16.17%, Excess +9.07%, Beat mkt rate 68.2%

120 days after: historical avg +17.17%

20-day -1.05%
60-day +4.51%
120-day +17.17%
20-day
60-day
120-day
Win
52.2%
47.8%
72.7%
Sample
23
23
22
Median
+0.6%
-4.34%
+16.17%
Excess
-1.66%
+1.73%
+9.07%
Beat mkt rate
43.5%
43.5%
68.2%

Over 22 occurrences, 120-day forward avg gained 17.17%, beat the market by 9.07 pts; win rate 72.7%.

Top-quintile 6-month momentum

Active · now 98.3%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
29 historical occurrences (since 2016-09-13)

Average forward return after Top-quintile 6-month momentum

20-day: Win 55.2%, Sample 29, Median +1.84%, Excess -1.96%, Beat mkt rate 51.7%

60-day: Win 67.9%, Sample 28, Median +6.1%, Excess +0.91%, Beat mkt rate 46.4%

120-day: Win 67.9%, Sample 28, Median +14.37%, Excess +4.12%, Beat mkt rate 60.7%

120 days after: historical avg +13.77%

20-day -1.04%
60-day +6.73%
120-day +13.77%
20-day
60-day
120-day
Win
55.2%
67.9%
67.9%
Sample
29
28
28
Median
+1.84%
+6.1%
+14.37%
Excess
-1.96%
+0.91%
+4.12%
Beat mkt rate
51.7%
46.4%
60.7%

Over 28 occurrences, 120-day forward avg gained 13.77%, beat the market by 4.12 pts; win rate 67.9%.

Filed revenue acceleration

Active · now 41.15%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

18 historical occurrences (since 2018-05-10)

Average forward return after Filed revenue acceleration

20-day: Win 44.4%, Sample 18, Median -4.99%, Excess -0.23%, Beat mkt rate 50%

60-day: Win 38.9%, Sample 18, Median -6.62%, Excess -2.35%, Beat mkt rate 33.3%

120-day: Win 52.9%, Sample 17, Median +8.62%, Excess +0.13%, Beat mkt rate 47.1%

120 days after: historical avg +5.52%

20-day -1.13%
60-day +0.43%
120-day +5.52%
20-day
60-day
120-day
Win
44.4%
38.9%
52.9%
Sample
18
18
17
Median
-4.99%
-6.62%
+8.62%
Excess
-0.23%
-2.35%
+0.13%
Beat mkt rate
50%
33.3%
47.1%

Over 17 occurrences, 120-day forward avg gained 5.52%, beat the market by 0.13 pts; win rate 52.9%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 147+41.3% +34.2% 100% +23.7%
20-40 480+29.3% +30% 92.9% +9.4%
40-60 137-6.9% -26.1% 45.3% -24.7%
60-80 5Insufficient data
80-100 You are here0Insufficient data

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 39.08, placing it in the 82.1 own-history percentile, inside the 80-100 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+12.4%
Win rate 75.9% Excess +1.9%
319d
-9.6%
Win rate 24.2% Excess -17.9%
186d
Now
Insufficient data
(1d)
60-day momentum down
+18.2%
Win rate 95.6% Excess +9.6%
271d
+31.2%
Win rate 80.4% Excess +21.6%
112d
Insufficient data
(0d)

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

31 times historically; 60-day forward avg +6.21%, win rate 57.1%, beating the market by +2.99 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.